Helping Biotron to Do Better and Deliver Tangible Results: Shareholders Call for ASIC Action and Regulatory Scrutiny, page-111

It should have been obvious to Biotron (BIT) management that C14 would not deliver results quickly. They had ample time to act when the share price was trading above 8 cents. That would have been the right moment to raise capital or encourage option conversions. But they didn’t. This delay doesn’t appear to be a mistake—it looks deliberate. It seems designed to allow insiders to benefit, acquiring cheap shares while reshaping the story to suit their own timeline.

C14 appears to be a strategic service provider, not to secure partnerships quickly, but to help biotech companies like BIT buy time—giving management room to delay action, shift focus, and introduce new narratives to avoid accountability. In this case, the partnership with C14 has served to deflect attention from internal failures while giving the impression that progress is being made.

Now, they’re likely waiting for the shortfall in the current capital raise to be filled—possibly by selected insiders or new investors, again at bargain pricing. All of this appears to be structured in a way that lets management stay in control, keep drawing salaries, and reposition the company—not for shareholder benefit, but for their own.

C14 seems to be helping Biotron reshape its business strategy in a way that continues to serve management’s interests. That’s what’s clearly visible now. The only question is: is there more to it than what we see? Perhaps GY can look deeper and uncover what others might be missing.